<DOC>
	<DOCNO>NCT00117455</DOCNO>
	<brief_summary>The purpose study evaluate ability two different fix dos pegfilgrastim ( 6mg 12mg ) by-weight dose filgrastim ( 5ug/kg/day ) mobilisation collection PBPCs autologous transplantation chemotherapy .</brief_summary>
	<brief_title>A Study Peripheral Blood Progenitor Cell ( PBPC ) Mobilisation Chemotherapy With Pegfilgrastim Filgrastim Subjects With Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Subjects nonHodgkin 's lymphoma ( NHL ) consider suitable candidate autologous PBPC transplantation per institution guideline ECOG 02 inclusive ANC great 1.5 x 10^9/L ; PLT great 100 x 10^9/L Exclusion Criteria : More one line ( regimen ) previous chemotherapy treatment 2 cycle premobilisation salvage chemotherapy prior enrolment . Patients also exclude study receive salvage chemotherapy contain follow agent : procarbazine , nitrogen mustard , nitrosoureas ( include BCNU ) , melphalan fludarabine . Previous bone marrow PBPC transplant Greater 20 % bone marrow involvement disease time screening , demonstrate biopsy Prior total nodal irradiation radiotherapy past 4 week Serum creatinine great 1.5 x upper limit institutional normal range Total serum bilirubin great 2 x upper limit institutional normal range Current diagnosis splenomegaly related lymphoma History prior malignancy , except lymphoma , curatively treat basal cell carcinoma , squamous cell carcinoma , insitu cervical carcinoma surgically cured malignancy Any premalignant myeloid condition malignancy myeloid characteristic ( e.g. , myelodysplastic syndrome , acute chronic myelogenous leukaemia ) Significant nonmalignant disease , include document HIV infection , uncontrolled hypertension ( diastolic blood pressure great 115 mmHg ) , unstable angina , congestive heart failure ( great NY Heart Association Class II ) , poorly control diabetes , coronary angioplasty within 6 month , uncontrolled atrial ventricular cardiac arrhythmia , active hepatitis C Haematopoietic growth factor administer within 1 week study entry . If growth factor support give previous chemotherapy cycle , WBC le 15.0 x 10^9/L required enrolment Treatment Interferon® last 3 month Known hypersensitivity E. coliderived pharmaceutical product ( e.g. , filgrastim , HUMULIN® insulin , Lasparaginase ) Subject previously randomise study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>ICE</keyword>
	<keyword>BEAM</keyword>
	<keyword>PBPC transplant</keyword>
</DOC>